Evidence map›Paper›PMID 28698754›Full record

ArticleOpen access Macedonian journal of medical sciences2017

Early and Late Complications in Patients with Allogeneic Transplantation of Hematopoietic Stem Cell - Case Report.

Ivana Trajkovska, Borce Georgievski, Lidija Cevreska, Andrijana Gacovski, Taner Hasan, Natasha Nedeska-Minova

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Open access Macedonian journal of medical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ivana TrajkovskaGOB "8-mi Septemvri" Skopje, Skopje, Republic of Macedonia.
Borce GeorgievskiUniversity Clinic of Hematology, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia.
Lidija CevreskaUniversity Clinic of Hematology, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia.
Andrijana GacovskiPrimary Health Care "D-r Vasileva Cardio", Skopje, Republic of Macedonia.
Taner HasanGOB "8-mi Septemvri" Skopje, Skopje, Republic of Macedonia.
Natasha Nedeska-MinovaGOB "8-mi Septemvri" Skopje, Skopje, Republic of Macedonia.
Institute of public health of Republic of Macedonia · MKSs. Cyril and Methodius University in Skopje · MK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAllogeneic hematopoietic stem cells transplantation (HSCT) is a curative intervention in patients with haematological malignant and non-malignant diseases, immunodeficiency, autoimmune, and other genetic diseases. Early complications are complications that are occurring in the first 100 days, while complications arising after the 100th day of transplantation belong to late complications. CASE REPORT: Forty-nine years old patient with AML treated with allogeneic HSCT from HLA-identical (sister) donor. Ascertained and display of early (acute Graft versus host disease (GvHD) and late complications (chronic GVHD, infections, cataract, secondary malignancy with MS deposits) are made, that emerged after the patient transplantation.

conclusionRapidly growing population of patients that undergo allogeneic HSCT creates an obligation to educate patients and physicians about observed late complications that occur after this therapy.

Indexed as

allogeneic hematopoietic stem cells transplantationearly and late complicationsgraft versus host diseasesecondary malignancy

Identifiers

PMID28698754
PMCPMC5503734
OpenAlexW2613185692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.